Clinical trials investigated a range of strategies, including CSF1R inhibition (e.g., cabiralizumab, PLX3397), TAM reprogramming strategies, checkpoint blockade, and combination therapies with PARP inhibitors, radiotherapy, and vaccines.<h4>Conclusion</h4>The integration of bibliometric insights with clinical trial and published data highlights the increasing translational focus on TAM/TME-targeted therapies in PCa. The gene discussed is CSF1R; the disease is posterior cortical atrophy.